CAPRICOR THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.3M | $29.7M | $4.2M | $3.2M | $2.2M | $1.3M | $1.4M |
| Grant Revenue | — | — | $3.2M | $2.8M | $3.2M | $2.2M | $1.3M | $1.4M |
| Collaboration and License Revenue | — | — | $26.5M | $1.5M | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $84.5M | $50.0M | $36.4M | $21.8M | $13.6M | $8.5M | $5.1M | $12.1M |
| SG&A Expense | $23.7M | $14.9M | $12.8M | $10.4M | $7.6M | $5.5M | $3.6M | $4.9M |
| Operating Income | $-108.1M | $-42.6M | $-24.1M | $-29.7M | $-20.9M | $-13.7M | $-7.7M | $-15.3M |
| Operating Margin | — | -191.1% | -81.2% | -701.4% | -655.1% | -627.1% | -593.1% | -1,065.9% |
| Interest Expense | — | — | — | — | — | — | — | $0 |
| Pretax Income | $-105.0M | $-40.5M | — | — | — | — | — | — |
| Income Tax Expense | $1.6K | $1.6K | — | — | — | — | — | — |
| Net Income | $-105.0M | $-40.5M | $-22.3M | $-29.0M | $-20.0M | $-13.7M | $-7.6M | $-15.2M |
| Net Margin | — | -181.7% | -75.1% | -685.4% | -626.5% | -625.6% | -586.0% | -1,056.4% |
| EPS (Basic) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 | $-0.88 | $-0.52 | $-1.29 |
| EPS (Diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 | $-0.88 | $-0.52 | $-0.13 |
| Shares Outstanding (Basic) | 46.5M | 35.2M | 26.8M | 24.6M | 23.1M | 15.6M | 14.8M | 11.8M |
| Shares Outstanding (Diluted) | 46.5M | 35.2M | 26.8M | 24.6M | 23.1M | 15.6M | 14.8M | 11.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |